Молимо вас користите овај идентификатор за цитирање или овај линк до ове ставке: https://scidar.kg.ac.rs/handle/123456789/11117
Назив: Profile of evolocumab and its cost-effectiveness in patients with high cardiovascular risk: literature review
Аутори: Jankovic, Slobodan
Tesic D.
Anđelković J.
Kostic M.
Датум издавања: 2018
Сажетак: © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Evolocumab is fully human monoclonal antibody which binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), and prevents its blocking effect on recycling of liver low-density lipoprotein (LDL) receptors. Areas covered: The aim of this review is to assess efficacy, safety, and cost-effectiveness of evolocumab in adult patients with high cardiovascular risk. Major research databases MEDLINE, EBSCO, and CENTRAL were systematically searched for relevant study reports. Expert commentary: Even when given in full doses, statins augmented with ezetimibe and cholesterol-binding resins could not reduce cholesterol baseline level for more than 66%, while evolocumab reduces cholesterol level for 75% or even more. Up to now, evolocumab showed good safety profile, and patents tolerate it very well. The abovementioned advantages of evolocumab made it almost ideal drug for hypercholesterolemia, and probably in the future the best drug for secondary prevention of major cardiovascular events. Evolocumab is borderline cost-effective for the treatment of patients with high cardiovascular risk in European countries, while in the U.S.A. it is under debate where the underlying assumption (risk of cardiovascular disease events) determine the true value.
URI: https://scidar.kg.ac.rs/handle/123456789/11117
Тип: article
DOI: 10.1080/14737167.2018.1501679
ISSN: 1473-7167
SCOPUS: 2-s2.0-85050701171
Налази се у колекцијама:Faculty of Medical Sciences, Kragujevac

Број прегледа

56

Број преузимања

4

Датотеке у овој ставци:
Датотека Опис ВеличинаФормат 
PaperMissing.pdf
  Ограничен приступ
29.86 kBAdobe PDFСличица
Погледајте


Ставке на SCIDAR-у су заштићене ауторским правима, са свим правима задржаним, осим ако није другачије назначено.